论文部分内容阅读
目的探讨基因ERCC1、RRM1、TYMS、TUBB3表达的应用晚期非小细胞肺癌个体化化疗疗效和预后的影响。方法将2012年10月至2014年10月72例晚期非小细胞肺癌化疗患者随机分为两组,对照组采用DP(多西紫杉醇+顺铂)方案,研究组进行ERCC1、RRM1、TYMS、TUBB3基因的m RNA表达水平检测,并根据检测结果针对性地选择DP方案、DF(多西紫杉醇+5-FU)方案、GP(吉西他滨+顺铂)方案、GF(吉西他滨+5-FU)方案、DPF(多西紫杉醇+顺铂+5-FU)方案。观察两组患者的不良反应、生活质量、化疗有效率(RR)和中位生存时间(m OS)。结果研究组的有效率明显高于对照组(80.0%vs 56.2%,P<0.05);研究组与对照组m OS分别为16.7个月和12.2个月,差异有统计学意义(P<0.05);对照组不良反应包括骨髓抑制、肝肾损害,其发生率均明显高于研究组(P<0.05);两组生活质量改善率比较差异也有统计学意义(P<0.05)。结论 ERCC1、RRM1、TYMS、TUBB3联合检测及基于其基础上的个体化化疗对晚期非小细胞肺癌患者具有安全性高、针对性强、毒副作用小等优点,明显改善患者预后,提高患者的生活质量。
Objective To investigate the effect of the expression of ERCC1, RRM1, TYMS and TUBB3 on the curative effect and prognosis of advanced non-small cell lung cancer (NSCLC) patients undergoing chemotherapy. Methods Seventy-two patients with advanced non-small cell lung cancer who underwent chemotherapy from October 2012 to October 2014 were randomly divided into two groups. The control group was treated with DP (docetaxel + cisplatin). The study group was treated with ERCC1, RRM1, TYMS, TUBB3 According to the results of the detection, DP, DF (docetaxel + 5-FU), GP (gemcitabine + cisplatin) and GF (gemcitabine + 5-FU) DPF (docetaxel + cisplatin + 5-FU) regimen. Adverse reactions, quality of life, chemotherapy response (RR) and median survival time (m OS) were observed in both groups. Results The effective rate of the study group was significantly higher than that of the control group (80.0% vs 56.2%, P <0.05). The m OS of the study group and the control group were 16.7 months and 12.2 months, respectively, with significant difference (P <0.05) ; Adverse reactions in the control group, including myelosuppression, liver and kidney damage, the incidence was significantly higher than the study group (P <0.05); two groups of quality of life improvement was also statistically significant difference (P <0.05). Conclusion The combined detection of ERCC1, RRM1, TYMS and TUBB3 and their individualized chemotherapy based on the advantages of high safety, strong pertinence and small toxic and side effects in patients with advanced non-small cell lung cancer can significantly improve the prognosis and improve the life of patients quality.